FIELD: medicine, phthisiology, pharmacy. SUBSTANCE: invention relates to medicinal agents used in treatment of tuberculosis patients. An anti-tuberculosis preparation represents a pharmaceutical composition containing isoniazide (isonicotinic acid hydrazide) taken in the dose 5-15 mg/kg; 2,4-dioxo-5-fluoropyrimidine (fluorouracil) taken in the dose 0.1-2.5 mg/kg and pharmaceutically acceptable carrier. Ratio of isoniazide to fluorouracil can be equal (2:1)-(150:1) by the weight. Composition can be made as solution and administrated by intramuscular or intravenous route. Preparation shows high an anti-tuberculosis activity with combination of reduced toxic effect. EFFECT: enhanced and valuable medicinal properties of preparation. 4 cl, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR TREATING THE CASES OF TUBERCULOSIS | 2002 |
|
RU2212240C1 |
METHOD FOR TREATING THE CASES OF EXPERIMENTAL TUBERCULOSIS | 2000 |
|
RU2165761C1 |
METHOD OF TREATMENT OF EXPERIMENTAL TUBERCULOSIS | 2001 |
|
RU2207127C1 |
DRUG PREPARATION FOR TREATING TUBERCULOSIS | 2013 |
|
RU2523792C9 |
METHOD FOR TREATING TUBERCULOSIS | 2004 |
|
RU2269346C1 |
TUBERCULOSTAT AGENT | 2001 |
|
RU2185170C1 |
TUBERCULOSTATIC AGENT | 2002 |
|
RU2207126C1 |
METHOD OF REDUCING INTOLERANCE TO ANTITUBERCULOUS PREPARATIONS | 2009 |
|
RU2412701C2 |
METHOD OF TREATING INFILTRATIVE PULMONARY TUBERCULOSIS INDUCED BY MULTIPLE-DRUG-RESISTANT AND HIGHLY TOXIC STRAINS OF MYCOBACTERIA TUBERCULOSIS | 2009 |
|
RU2423129C1 |
METHOD FOR EVALUATING THE SEVERITY OF TUBERCULOSIS INFECTION | 2005 |
|
RU2305286C2 |
Authors
Dates
2003-08-27—Published
2002-03-18—Filed